Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Cincinnati, Ohio 45267


Purpose:

The purpose of this research study is to find out what effects (good and bad) that omega-3 fatty acids has on schizophrenia.


Study summary:

The two aims of the study test the hypotheses that correcting omega-3 fatty acid deficiency in the early stages of schizophrenia improves positive symptom treatment response, negative symptom treatment response, and cognition symptom response.


Criteria:

Inclusion Criteria: - Between the ages of 8-25 years. - Diagnosis of MDD and not exhibited symptom remission CDRS-R (> 28 but < 40) despite being administered a standard therapeutic dose of an SSRI continuously for a minimum of 6 weeks. - Ability and willingness to provide assent and informed, written consent from at least one biological parent. - Present with biological parent or legal guardian. - Willingness to maintain current dietary habits. - Permission from treating physician - Able to perform fMRI/MRS. Exclusion Criteria: - Inability or unwillingness to provide consent. - Antecedent or concurrent serious medical illness. - Clinically unstable medical disease, including cardiovascular, hepatic insufficiency, severe renal impairment, gastrointestinal, pulmonary, metabolic, endocrine, obesity or other systemic disease. - History of seizures, excluding febrile seizures in childhood. - Patients requiring treatment with any drug which might obscure the action of the study treatment. - Female patients who are either pregnant or lactating. - Clinically significant laboratory abnormalities in the last year on CBC or TSH tests. - Judged clinically to be at suicidal risk (defined as having active suicidal ideation, intent or plan, or a serious suicide attempt within the past 6 months, or a baseline CDRS-R suicide score of >3). - Hospitalized within the last 3 months - Greater than 1 year outside appropriate age/grade level - Pacemaker - Cerebral aneurysm clip - Cochlear implant - Metal fragments lodged within the eye or braces - Claustrophobia - Necessity of sedation (no sedation will be given). - History of loss of consciousness > 10 minutes in duration - Allergy to seafood.


NCT ID:

NCT00585390


Primary Contact:

Principal Investigator
Neil Richtand, MD
Unversity of Cincinnati


Backup Contact:

N/A


Location Contact:

Cincinnati, Ohio 45267
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: March 16, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.